B25.0 Cytomegaloviral pneumonitis

Name of the Condition

• Cytomegaloviral pneumonitis

Summary

Cytomegaloviral pneumonitis is a lung infection caused by the cytomegalovirus (CMV), a member of the Herpesviridae family. It primarily affects individuals with weakened immune systems, leading to inflammation and potential respiratory compromise. The condition can range from mild to severe, with symptoms depending on the extent of lung involvement and the patient's immune status.

Causes

The infection is caused by the cytomegalovirus (CMV), which is transmitted through direct contact with infected bodily fluids (e.g., saliva, urine, blood, or respiratory secretions). Primary infection occurs when the virus enters the body, and reactivation can happen in immunocompromised individuals. Congenital transmission from mother to fetus during pregnancy is also possible.

Risk Factors

• Immunocompromised states, including HIV/AIDS, organ transplantation, or immunosuppressive therapy.
• Neonates and infants, particularly those born to mothers with primary CMV infection during pregnancy.
• Close contact with individuals shedding the virus (e.g., in healthcare or daycare settings).
• Advanced age, which may be associated with declining immune function.

Symptoms

• Cough (often dry or productive).
• Shortness of breath or difficulty breathing.
• Fever.
• Fatigue and malaise.
• Chest discomfort or pain.
• In severe cases, respiratory failure may occur.

Diagnosis

Diagnosis involves a combination of clinical evaluation, laboratory tests, and imaging. Blood tests may detect CMV antibodies or DNA. Respiratory samples (e.g., sputum, bronchoalveolar lavage) can be tested for viral presence. Chest imaging (e.g., X-ray or CT scan) may show characteristic patterns of lung inflammation. In some cases, a lung biopsy may be performed to confirm the diagnosis.

Treatment Options

Treatment focuses on antiviral therapy, such as ganciclovir or valganciclovir, to reduce viral replication. Supportive care, including oxygen therapy or mechanical ventilation, may be necessary for severe respiratory symptoms. Management of underlying immunosuppression (e.g., adjusting medications) is also critical. In some cases, immune globulin therapy may be considered.

Prognosis and Follow-Up

Prognosis depends on the patient's immune status and the severity of lung involvement. Immunocompetent individuals often recover fully with treatment, while immunocompromised patients may experience prolonged or recurrent infections. Regular follow-up with imaging and viral load monitoring is recommended to assess response to therapy and detect recurrence.

Complications

• Respiratory failure requiring mechanical ventilation.
• Secondary bacterial or fungal infections.
• Chronic lung damage or fibrosis in severe cases.
• Dissemination of the virus to other organs (e.g., liver, kidneys).

Lifestyle & Prevention

• Practice good hand hygiene, especially after contact with bodily fluids.
• Avoid close contact with individuals showing signs of active CMV infection.
• For immunocompromised patients, discuss prophylactic antiviral therapy with a healthcare provider.
• Pregnant individuals should avoid exposure to known CMV sources and seek prenatal care.

When to Seek Professional Help

Seek immediate medical attention if you experience severe shortness of breath, high fever, or chest pain. Prompt evaluation is critical for immunocompromised individuals or those with suspected CMV exposure, as early treatment can improve outcomes.

Tips for Medical Coders

When coding for cytomegaloviral pneumonitis, use ICD-10-CM code B25.0. Ensure documentation supports the diagnosis, including clinical findings, laboratory results, and imaging. Note any underlying immunocompromised status or risk factors, as these may impact coding specificity. Verify that the code aligns with the patient's clinical presentation and documented provider assessment.